AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 262 min read$ROIV

Venker Eric sold $6.6M of ROIV

Venker Eric (President & Immunovant CEO) sold 200,000 shares of Roivant Sciences Ltd. (ROIV) at an average of $33.16 ($33.05–$33.51, $6.63M total) across 2 trades on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Venker Eric
Published Jun 26, 2026, 10:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 10:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ROIV
Neutral
medium confidence
Mentioned
$ROIV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROIVNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on executive selling activity (200,000 shares; ~$6.63M) but does not include new operational, clinical, or financial guidance.

02

Market read

Useful for monitoring insider behavior, but the 10b5-1 framing suggests limited incremental trading edge versus broader catalysts.

03

What to watch

Traders may over-weight insider-sale headlines; the key incremental data here is only the disclosed sale size/price and remaining holdings, not new company fundamentals.

Relevance 5/10Novelty 5/10Timing: after-hours/filing date (2026-06-26) for a 2026-06-24 sale

Background

This is an SEC Form 4 insider transaction for Roivant Sciences Ltd., reported via EDGAR.

Company-level read

Ticker impact

$ROIVNeutralMedium confidence
Context

Roivant Sciences insider Venker Eric (President & Immunovant CEO) sold 200,000 shares in open-market trades on 2026-06-24 under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any reaction should be muted given the pre-arranged 10b5-1 structure.

Evidence & confidence

Form 4 discloses the sale size, price range, and 10b5-1 pre-arrangement, which typically reduces interpretive signal versus discretionary selling.

Market effects

Sector

No direct sector read-through; this is company-specific insider transaction disclosure.

Regional

None indicated; US-listed issuer filing.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • issuer
    Roivant Sciences Ltd.

    Subject of the Form 4 insider sale by its President & Immunovant CEO.

  • insider
    Eric Venker

    Officer (President & Immunovant CEO) who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ROIV insider trading history →

Related articles

OCT 5
$ROIVMedAI 8/10

Transcript: Roivant Sciences Q1 2027 Earnings Conference Call - Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences (ROIV) reported Q1 2026 results, highlighting a quiet quarter with progress in its pipeline, particularly brepocitinib's Phase 3 study. The company received a $950M settlement from Moderna and has ongoing litigation against Pfizer and BioNTech. Financially, ROIV reported $200M in R&D expenses, $100M in non-GAAP G&A expenses, and a cash position of nearly $4B. Management expects a busy second half with brepocitinib's launch and other pipeline updates.

benzinga.com3 min
OCT 5
Med

Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya

Roivant Sciences, a biopharma company with a unique hub-and-spoke model, is transitioning into a commercial phase with the launch of Lisraya, an oral TYK2/JAK inhibitor for dermatomyositis. CEO Matt Gline aims to differentiate the company with a commercial portfolio, including Lisraya, Pulmovant’s mosliciguat, and Immunovant’s IMVT-1402. Leerink Partners estimates Lisraya could generate $7.9 billion in sales by 2035, with mosliciguat's expectations raised to $9.8 billion.

biospace.com3 min
SEP 24
$ROIVMedAI 8/10

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Roivant Sciences (ROIV) shares rose 17% after reporting positive Phase 2 results for mosliciguat, its experimental treatment for pulmonary hypertension. The drug met primary and secondary endpoints, reducing pulmonary vascular resistance by 56.3% and improving six-minute walk distance. J.P. Morgan estimates peak sales of $1.5B, though this is an analyst forecast. Roivant is now advancing to Phase 3 trials.

insidermonkey.com3 min